Vortex Energy Stock Quote VRTX - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

0.135

Bid

0.135

Ask

0.14

Volume

67,000

0.135 Day's Range 0.14

0.135 52 Week Range 1.30

Previous Close

0.135

Open

0.14

Last Trade

500

0.135

Last Trade Time

Average Volume (3m)

52,054

Financial Volume

VWAP

Vertex Pharmaceuticals Announces the Date of its Third Quarter 2006 Financial Results Conference Call and Webcast

CAMBRIDGE, Mass., Oct. 9 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) will announce its third quarter 2006 financial results on Thursday, October 26, 2006...

Vertex Pharmaceuticals Announces Completion of Common Stock Offering

CAMBRIDGE, Mass., Sept. 20 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) today announced the completion of its public offering of 9,100,000 shares of common...

Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences

CAMBRIDGE, Mass., Sept. 18 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) will webcast corporate presentations at Merrill Lynch's Global Pharmaceutical, Biotech...

Vertex Pharmaceuticals Announces Pricing of Common Stock Offering

CAMBRIDGE, Mass., Sept. 14 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) today announced the pricing of its public offering of 9,100,000 shares of its common...

Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680

Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680 WHITEHOUSE STATION, N.J. and CAMBRIDGE, Mass., June 17 /PRNewswire/ -- Merck & Co., Inc...

Vertex Pharmaceuticals Reports Positive Results from First-in-Human Study for VX-950, an Investigational Oral Protease Inhibitor

Vertex Pharmaceuticals Reports Positive Results from First-in-Human Study for VX-950, an Investigational Oral Protease Inhibitor for the Treatment of Hepatitis C -- Encouraging Results Support...

Studies of Sustained Efficacy/Tolerability of LEXIVA After 96 Weeks of Treatment Presented at IAC

Studies of Sustained Efficacy/Tolerability of LEXIVA After 96 Weeks of Treatment Presented at IAC BANGKOK, Thailand, July 13 /PRNewswire-FirstCall/ -- The protease inhibitor (PI) LEXIVA(R...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.01	-6.89655172414	0.145	0.145	0.135	101231	0.14146497	CS
4	-0.04	-22.8571428571	0.175	0.175	0.135	55810	0.14921363	CS
12	-0.1	-42.5531914894	0.235	0.235	0.135	52054	0.18253751	CS
26	-0.16	-54.2372881356	0.295	0.315	0.135	68007	0.22309216	CS
52	-1.085	-88.9344262295	1.22	1.3	0.135	164046	0.4718018	CS
156	0.035	35	0.1	2.32	0.1	227798	0.99316463	CS
260	0.035	35	0.1	2.32	0.1	227798	0.99316463	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
WESA.XWesana Health Holdings Inc	$ 0.015 (200.00%)	20k
MYNDMYND Life Sciences Inc	$ 0.04 (100.00%)	6k
GOHGoldHaven Resources Corp	$ 0.06 (71.43%)	67.1k
ASEPASEP Medical Holdings Inc	$ 0.145 (61.11%)	20k
PSYGPsyence Group Inc	$ 0.03 (50.00%)	1,000
PLAYPlayground Ventures Inc	$ 0.01 (-50.00%)	121.12k
ENRTEnertopia Corp	$ 0.01 (-50.00%)	3.41k
TANATana Resources Corp	$ 0.03 (-50.00%)	5k
WOGCWaskahigan Oil and Gas Corp	$ 0.03 (-50.00%)	2.06k
TGIITrojan Gold Inc	$ 0.03 (-40.00%)	9.43k
QIMCQuebec Innovative Materials Corp	$ 0.21 (5.00%)	3.49M
PKKPeak Fintech Group Inc	$ 0.08 (-5.88%)	3.33M
HZHertz Energy Inc	$ 0.08 (14.29%)	1.42M
NEWSNew World Solutions Inc	$ 0.02 (0.00%)	1.31M
SANUSanu Gold Corp	$ 0.06 (9.09%)	986.55k